secwatch.observer — SEC 8-K summary
======================================

Issuer:     Insight Molecular Diagnostics Inc. (IMDX)
CIK:        0001642380
Form:       8-K
Filed at:   2024-08-09T23:59:59+00:00
Accession:  0001493152-24-030865
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 1.01, 1.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Oncocyte enters $7.5M ATM with Needham, terminates prior $50M BTIG ATM
----------------------------------------------------------------------

- Enters Sales Agreement with Needham & Company for up to $7.5M of common stock at-the-market.
- Terminates prior ATM agreement with BTIG, LLC dated June 11, 2021 for up to $50M.
- Company may sell shares from time to time; Needham receives 3.0% commission on gross proceeds.
- Net proceeds intended for working capital and general corporate purposes.
- Placement shares registered under S-3 effective August 7, 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1642380/000149315224030865/0001493152-24-030865-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1642380/000149315224030865/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-030865

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer